Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
MethylGene Inc, in collaboration with Pharmion Corp, is developing the small-molecule, isoform-selective compound MGCD-0103 in North America for the potential treatment of cancer. MGCD-0103 is currently undergoing phase II clinical trials in patients with lymphoma, leukemia, myelodysplastic syndromes and solid tumors, including pancreatic carcinoma. Taiho Pharmaceutical Co Ltd is evaluating MGCD-0103 for oncological indications in South East Asia.
Kell
Jonathan
J
Address University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK. Jonathan.Kell@cardiffandvale.wales.nhs.uk
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001549:Benzamides / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D011743:Pyrimidines / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D011743:Pyrimidines; C523184:mocetinostat